Phar Vision Advisers, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Phar Vision Advisers, LLC
- $178 Billion
- Q3 2025
A detailed history of Phar Vision Advisers, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Phar Vision Advisers, LLC holds 12,329 shares of CPRX stock, worth $285,786. This represents 0.14% of its overall portfolio holdings.
Number of Shares
12,329Holding current value
$285,786% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
394Shares Held
106MCall Options Held
164KPut Options Held
439K-
Black Rock Inc. New York, NY18.7MShares$433 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.71MShares$202 Million0.0% of portfolio
-
State Street Corp Boston, MA6.41MShares$148 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.97MShares$115 Million1.82% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.54MShares$82.2 Million0.1% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.38B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...